Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

Can plasma %p-tau217 and eMTBR-tau243 be combined to approximate an amyloid and tau positron emission tomography (PET)–based Alzheimer disease biological staging scheme?In 872 BioFINDER-2 participants and 156 independent Knight Alzheimer Disease Research Center participants, a plasma model combining %p-tau217 and eMTBR-tau243 showed strong concordance with PET-based biological staging and outperformed a %p-tau217–only model, particularly for identifying the intermediate tau stage. Advanced plasma stages also aligned with greater clinical severity, other biomarker abnormalities, and neuropathologic burden.Plasma-based staging may provide a scalable, minimally invasive approach to biological stratification of Alzheimer disease, with potential value for treatment selection and clinical trial enrichment.

Corresponding Authors: Gemma Salvadó, PhD (gemma.salvado@med.lu.se), and Oskar Hansson, MD, PhD (oskar.hansson@med.lu.se), Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, S:t Johannesgatan 8, 211 46 Malmö, Sweden.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.